Analysis of ABCG2 Genotype in Gleevec Treated Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (C421A) in ABCG2 and Response to Treatment
ABCG2, also known as breast cancer resistance protein (BCRP), is an ATP-binding cassette
(ABC) transporter that has been shown to confer resistance to several drugs, including
mitoxantrone and topotecan. Gleevec (imatinib mesylate) has recently been identified as a
substrate for ABCG2. The expression of ABCG2 in the human jejunum has been shown to be
higher than expression MDR1, which encodes for P-glycoprotein. Therefore, it is plausible
that the oral bioavailability of Gleevec could be dependent on the extent of transport. A
single nucleotide polymorphism (C421A) has been identified in ABCG2 and has been shown in
vitro to result in functional inactivation of this transporter protein. In this study, the
relationship between the genotypes of ABCG2 and the pharmacokinetics or side effects will be
retrospectively explored in patients with cancer who had been previously enrolled on
clinical trials of Gleevec.
Observational
N/A
United States: Federal Government
999905090
NCT00342056
January 2005
October 2008
Name | Location |
---|---|
Washington Hospital Center | Washington, District of Columbia 20010 |